These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1678272)

  • 1. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.
    MacDonald NJ; Grant AC; Rodger RS; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1991 Jun; 31(6):697-700. PubMed ID: 1678272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.
    Wensing G; Branch RA; Humbert H; Ohnhaus EE; Kirch W
    Eur J Clin Pharmacol; 1990; 39(6):569-72. PubMed ID: 1982762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
    Drewe J; Meier R; Timonen U; Thumshirn M; Munzer J; Kissel T; Gyr K
    Br J Clin Pharmacol; 1991 Jun; 31(6):671-6. PubMed ID: 1678271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bopindolol: long-term effects on blood pressure, renal function, plasma renin activity, and plasma aldosterone in mild-to-moderate essential hypertension.
    Shohat J; Modan M; Rosenfeld JB
    Fundam Clin Pharmacol; 1989; 3(1):53-8. PubMed ID: 2565862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bopindolol, a new long-acting beta-adrenoceptor antagonist--a randomized comparison against propranolol in hypertensive patients.
    Kirch W; Axthelm T
    Int J Clin Pharmacol Res; 1983; 3(2):89-93. PubMed ID: 6148312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
    Aellig WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S12-5. PubMed ID: 2439811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bopindolol: Czechoslovak experience with a new beta blocker in the treatment of hypertension.
    Widimský J; Lefflerová K; Dvorák I; Fedelesová V; Lupínek Z; Mayer O; Pinterová E
    Am J Cardiol; 1991 Apr; 67(10):36B-42B. PubMed ID: 1673580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.
    Holmes D; Nuesch E; Houle JM; Rosenthaler J
    Eur J Clin Pharmacol; 1991; 41(2):175-8. PubMed ID: 1683836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bopindolol on renal function.
    Fabre J; Wintsch J; Peter-Contesse R; Bouchardy C; Liniger C; Favre L; Donath A
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S45-50. PubMed ID: 2439819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bopindolol: a slowly dissociating antagonist from the beta-adrenoceptors in guinea pig atria.
    Hosohata Y; Hattori K; Shen Y; Okuyama M; Kaneko H; Ohnuki T; Suzuki J; Nagatomo T
    Pharmacology; 1998 Oct; 57(4):180-7. PubMed ID: 9730775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers.
    Dayer P; Mérier G; Perrenoud JJ; Marmy A; Leemann T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S20-4. PubMed ID: 2439813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The affinity of bopindolol and its two metabolites for a beta 2-adrenoceptor in the bovine mesenteric artery.
    Hosohata Y; Suzuki M; Karakisawa Y; Maruyama K; Nagatomo T
    Biol Pharm Bull; 1994 Sep; 17(9):1296-8. PubMed ID: 7841957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous and oral pindolol in hypertensive patients with chronic renal failure.
    Safar ME; Chau NP; Levenson JA; Simon AC; Weiss YA
    Clin Sci Mol Med Suppl; 1978 Dec; 4():275s-277s. PubMed ID: 282067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bopindolol: pharmacological basis and clinical implications.
    Nagatomo T; Hosohata Y; Ohnuki T; Nakamura T; Hattori K; Suzuki J; Ishiguro M
    Cardiovasc Drug Rev; 2001; 19(1):9-24. PubMed ID: 11314603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The antihypertensive efficacy and tolerance of bopindolol (LT 31-200) in hypertensive patients].
    Honorato J; Galende I; Catalán M; Azanza JR
    Rev Med Univ Navarra; 1990; 34(2):90-4. PubMed ID: 1983366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bopindolol in the treatment of hypertension: a double blind study comparing bopindolol and metoprolol.
    Lefflerová K; Lupínek Z; Widimský J; Lupínková Z; Uhlír O; Miklis P; Zeman K; Zicha J
    Cor Vasa; 1989; 31(5):387-93. PubMed ID: 2575480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic oral administration of a new beta-blocker, bopindolol, on serum lipoprotein concentrations and blood pressure of spontaneously hypertensive rats.
    Ishihara T; Chin WP; Yoshida Y; Sun HT; Mitomi A; Ishibashi T; Tamura K; Imai S
    Arch Int Pharmacodyn Ther; 1989; 302():145-57. PubMed ID: 2576891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of once-daily bopindolol and atenolol for mild-to-moderate hypertension.
    Colnago R; Meregalli M; Turri D; Nazzari M; Fiorella G; Guffanti EE; Mazzola C
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):347-52. PubMed ID: 2887520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.